Precision medicine is a segment of the medical health field, and as a vertical segment, the most concerned about it is the capital market. The rapid growth of the global precision medical market has clearly become the “big cake†of the market, but even in the hot industry, it is also in the direction of investment.
Under the background that the macro economy is in the down cycle and the growth of traditional industries is weak, the market concerns of emerging industries (Aiji, net worth, information) that represent the frontier direction are particularly obvious. The current medical health and some of the segments involved. For example, precision medicine is an obvious example. Precision medicine, as an extremely professional vertical segment, enters the public's field of vision with the attention of the capital market.
According to the Global Cancer Report, the global precision medical market is growing rapidly, with a compound annual growth rate of 12% between 2005 and 2015. It is expected that the compound growth rate will reach 15% from 2015 to 2020, which is the growth rate of the pharmaceutical industry. 3 to 4 times.
In 2015, the Ministry of Science and Technology established the China Precision Medical Strategy Expert Group and plans to invest 60 billion yuan by 2030. Nowadays, precision medicine has been included in the national “13th Five-Year Plan†and has been selected into the “13th Five-Year Plan†and has become a national strategy.
It is worth noting that there are many unrelated business purchases in the market that claim to enter this field. This situation has caused many industry people to be vigilant and issue "industry overheating" and "bubble" sounds. . However, from the perspective of commercial applications and technological breakthroughs, precision medicine and related industries are still in their infancy. From the perspective of demand and industry development, there is no doubt that this area still has a huge space.
The main battlefield of precision medicine is in the field of cancer, and other studies such as cardiovascular disease and diabetes are also underway. Accurate medical treatment includes precise diagnosis and precise treatment. Diagnosis is the basis of treatment, and molecular diagnosis is the core of accurate diagnosis. US consultancy MarketsandMarkets said that the global molecular diagnostics market is nearly $6 billion in 2015 and is expected to grow to $9.3 billion by 2020, with a compound annual growth rate of around 10%, and the annual growth rate of China's molecular diagnostics market. More than 20%, twice the global level.
The 2016 American Society of Clinical Oncology (ASCO) report pointed out that the challenge of cancer is increasing, and it is estimated that the number of cancer patients diagnosed worldwide by 2030 will reach 22 million. The report also believes that there are five directions that are key to future cancer prevention and treatment: cancer stem cell research and intervention; faster, cheaper, and more advanced genomics technology; liquid biopsy; nanomedicine; medical IT technology. Among them, both genomics and liquid biopsy are related to the molecular diagnosis of tumors.
In terms of gene sequencing , the market for sequencing sequencing from 2007 to 2016 is growing at a rate of 50%, and is expected to maintain a growth rate of around 20% in the future. At present, the industrial pattern of the domestic gene sequencing market is: the upstream instrument reagent consumables are monopolized by foreign giants, and the domestic Huada Gene and other enterprises are breaking through the front view; the midstream sequencing services are currently in a shuffling stage due to low barriers to entry, and are expected to be dumped in the future. One batch; the downstream is larger, but the market is yet to be educated.
Since the development of the first generation technology in 1975, the current gene sequencing technology has been developed to the third generation, but the second generation gene sequencing technology is currently the commercial mainstream in the market.
High Purity Active Ingredients
The factory of Insen Biotech was built in 2011, and has 11 years experence of plant extracts and fruit powder production. We can manufacture lots of active ingredients with high purity over 98%, such as Resveratrol 98% from Polygonum cuspidatum, Capsaicin 95%-99% from Capsicum annuum, Peprine 95%-98% from Pepper Seed, etc. These High Purity Active Ingredients boost the health of people in some extent and are very popular in the market.
Natural Capsaicin,Capsaicin Crystal Powder,Paeoniflorin Extract,Natural Pepper Extract Powder
Hunan Insen Biotech Co., Ltd , https://www.insenhealth.com